TipRanks
pc:newro

Newronika

Via Torquato Tasso, 1 Cologno Monzese (MI), Lombardy 20093, IT
https://www.newronika.com/
Newronika is a global leader in advanced deep brain stimulation, specializing in the development of an adaptive DBS system. This innovative platform is designed to deliver precision therapy to improve symptom relief and reduce side effects for Parkinson's disease patients. The company focuses on expanding clinical validation and commercialization efforts, advancing its product pipeline, and fostering strategic collaborations in the medical device engineering and neuroscience sectors.

Leadership & Board

Current Number of Employees28
Current LinkedIn Followers5,789

Latest Estimated Valuation

Estimated Valuation―
Estimated Valuation―
Total Amount Raised$28M
Total Amount Raised$28M
Total Funding Rounds2
Total Funding Rounds2
Latest Funding Amount$14M
Latest Funding Amount$14M
Latest Funding RoundSeries B
Latest Funding RoundSeries B
Post-Money Valuation―
Post-Money Valuation―

Employee Trend

Newronika had 28 employees as of September 28, 2026. The number of employees increased by 0 (0.00%) week-over-week.
28Latest Employee Count
0(0.00%)Week-Over-Week Change
Employee Trend serves as a data-driven indicator of company growth and expansion. The measurement reflects how a company’s workforce size changes over time.

Social Trend

Newronika had 5,789 followers as of September 28, 2026. The number of followers increased by 26 (0.45%) week-over-week.
5,789Latest Followers Count
26(0.45%)Week-Over-Week Change
LinkedIn Follower Trend serves as a data-driven indicator of market interest and company visibility. The measurement reflects how a company’s LinkedIn follower count changes over time.

Funding Round

Funding Date
Funding Round
Amount Raised
Post-Money Valuation
Mar 13, 2025
Series B
$14.20M
―
Feb 13, 2025
Series B
$13.60M
―

Investors

Investor Name
Funding Round

Similar Companies

A snapshot of private companies similar to Newronika, helping you discover and navigate related company profiles.

Related News and Analysis